Cytori Therapeutics (NASDAQ:CYTX) is a not yet profitable marketer of tissue regeneration therapies based in San Diego. Cytori's proprietary platform employs adipose-derived stem and regenerative cells (ADRCs). The company receives regular revenues from sales of its Puregraft, and other systems to researchers and healthcare providers around the world. Cytori's product, and research grant revenue streams partially fund its investments into clinical development of its cell therapies for cardiovascular and burn therapies.
Pumped up for cardiovascular therapies
Cytori's future hangs heavily on the development of its cardiovascular disease therapeutic pipeline. Myocardial ischemia is a disease characterized by insufficient blood supply to heart muscle caused by a rupture along the coronary artery. Cytori, of course, would like to market its...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|